Camurus’ Oczyesa® receives marketing authorization for treatment of acromegaly in the EU

First subcutaneous, once-monthly octreotide for treatment of acromegaly For convenient self-administration with a pre-filled autoinjector pen LUND, Sweden, July 1, 2025 /PRNewswire/ — Camurus (NASDAQ STO: CAMX) today announced that the European Commission (EC) has granted Oczyesa®,…